KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Non Operating Income (2017 - 2025)

Bionano Genomics' Non Operating Income history spans 7 years, with the latest figure at $49000.0 for Q3 2025.

  • For Q3 2025, Non Operating Income rose 115.26% year-over-year to $49000.0; the TTM value through Sep 2025 reached -$3.5 million, up 79.83%, while the annual FY2024 figure was -$10.1 million, 41.22% up from the prior year.
  • Non Operating Income for Q3 2025 was $49000.0 at Bionano Genomics, down from $953000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $5.4 million in Q1 2025 and bottomed at -$16.9 million in Q4 2023.
  • The 5-year median for Non Operating Income is -$40000.0 (2021), against an average of -$1.1 million.
  • The largest YoY upside for Non Operating Income was 2357.58% in 2023 against a maximum downside of 42030.0% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $1.1 million in 2021, then plummeted by 103.78% to -$40000.0 in 2022, then plummeted by 42030.0% to -$16.9 million in 2023, then skyrocketed by 41.69% to -$9.8 million in 2024, then skyrocketed by 100.5% to $49000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Non Operating Income are $49000.0 (Q3 2025), $953000.0 (Q2 2025), and $5.4 million (Q1 2025).